Distal biceps ruptures in National Football League players: return to play and performance analysis.

BACKGROUND: Distal biceps ruptures are rare injuries that tend to occur at a younger age in high-level athletic populations. Data analyzing athletes' ability to return to play, as well as performance, after surgery for a distal biceps rupture are lacking. METHODS: All National Football League (NFL) players from the 2000-2016 seasons who were found to have a surgically treated distal biceps rupture were included. Analysis of performance and career length was conducted with a control group matched for position, age, experience, and performance statistics. Data for the cohort vs. control group, as well as before vs. after injury, were analyzed with the paired-samples Student t test, with P < .05 deemed statistically significant. RESULTS: We identified 35 NFL players for the study; 33 (94%) were able to return to sport at an average of 351.4 ± 123.9 days. Offensive linemen undergoing surgery played fewer games per season compared with the control group (P = .04). However, the average number of seasons after surgery and after the index date was not found to be significant (P > .05). Mean career length, as well as number of games per season, did not differ in the postsurgical group vs. control group (P > .05) for all other positions. Performance scores within skill players did not prove to be significant between the postoperative and control groups (P > .05). CONCLUSIONS: Distal biceps ruptures treated surgically in NFL players allow for return to play at a high rate. The level of performance after surgery is similar to that of the player before injury. On average, NFL career length does not appear to be affected after distal biceps surgery.

Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.

Plasmodium falciparum, the deadliest malarial parasite species, has developed resistance against nearly all man-made antimalarial drugs within the past century. However, quinine (QN), the first antimalarial drug, remains efficacious worldwide. Some chloroquine resistant (CQR) P. falciparum strains or isolates show mild cross resistance to QN, but many do not. Further optimization of QN may provide a well-tolerated therapy with improved activity versus CQR malaria. Thus, using the Heck reaction, we have pursued a structure-activity relationship study, including vinyl group modifications of QN. Certain derivatives show good antiplasmodial activity in QN-resistant and QN-sensitive strains, with lower IC(50) values relative to QN.